entertainment -WSS

entertainment

author：fashion 2025-09-27 23:02:33 - browse：2

Zachary Kirimi inside a pharmacy -- health policy coverage from STAT — Zachariah Kirimi is a pharmacist who uses the Maisha Meds app to help manage his inventory and offer subsidized products to patients. Courtesy Jack Hewson/Maisha Meds

WASHINGTON — For an app that helps pharmacies in Africa manage their medicines, the term “pharmacy benefit manager” has become a dirty word.

The organization, called Maisha Meds, plays the role of a middleman between international groups like USAID and the Gates Foundation and pharmacies. By definition, it’s a PBM. But since it’s a nonprofit company and it subsidizes medicines and tests aimed at promoting public health, it’s hesitant to describe itself that way.

“Because so many people kind of think of PBMs in the U.S. as the enemy, we don’t ourselves use that term,” said Maisha Meds’ founder and CEO, Jessica Vernon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Idaho abortion case may prompt more restrictions in other states

WSS

Caregivers of transplant patients call for more support, training

A Q&A with the global head of Boehringer Ingelheim's innovation unit

New England Journal of Medicine addresses racist history, slavery

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Caregivers of transplant patients call for more support, training

The future of health care in the House

focus

entertainment

Wikipedia

Activists slam private health insurers over coverage restrictions

FDA authorizes Novavax’s updated Covid

Anesthesiologist group: stop taking Ozempic before surgery

Stroke deaths set to near 10 million globally by 2050

Anesthesiologist group: stop taking Ozempic before surgery

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

At least 13 dead in Texas as scorching temps continue

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Was Amgen transparent enough on FDA's concern on cancer drug?

knowledge

Readout LOUD podcast: live from JPM 2024

FDA panel signals lack of confidence in Amgen cancer drug data

FDA rejects Alnylam's heart disease treatment over insufficient data

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Why Charlie Gard's case is so disturbing to Americans

Chemotherapy drug shortage eases slightly but still widespread

explore

focus

focus

entertainment